A Randomized Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Recruiting
18 years - 99 years
All
Phase
N/A
428 participants needed
1 Location
Brief description of study
This study compares 2 combinations of drugs to prevent graft-versus-host disease (GVHD): Tacrolimus/methotrexate and Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best for future transplant patients. The purpose of its companion study is to understand if the bacteria and proteins in your gut and body fluids can help doctors predict transplant outcomes.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Acute Leukemia,Chronic Myelogenous Leukemia (CML),Myelodysplasia,Lymphoma
-
Age: 18 years - 99 years
-
Gender: All
Age 18 years or older Patients with acute leukemia or chronic myelogenous leukemia w Patients with myelodysplasia/chronic myelomonocytic leukemia w Patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma Patients with lymphoma [follicular lymphoma, Hodgkin lymphoma,
Updated on
04 Aug 2024.
Study ID: 833146
Find a site
,
Your Information has been sent successfully.
Send a message
Enter your contact details to connect with study team
Primary Contact
